GLP-1 Drugs Boost US Growth
This is a US news story, published by Insider, that relates primarily to Goldman Sachs news.
US news
For more US news, you can click here:
more US newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsInsider news
For more news from Insider, you can click here:
more news from InsiderAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
US obesity rate. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest poor health outcomes news, health advancements news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
lower obesity ratesInsider
•The more Americans who take Ozempic, the faster the US economy could grow, Goldman Sachs says
87% Informative
Goldman Sachs predicted that US GDP could jump by 1% if 60 million Americans took GLP-1 drugs by 2028 .
Goldman Sachs said health-related problems keep people from participating in the labor force and inhibit economic growth.
One spillover effect could be an increase in productivity, Hatzius said.
VR Score
95
Informative language
98
Neutral language
63
Article tone
formal
Language
English
Language complexity
53
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
3
Source diversity
1
Affiliate links
no affiliate links